Zensar Technologies shines on acquiring BridgeView Life Sciences LLC
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zensar Technologies is currently trading at Rs. 791.25, up by 12.40 points or 1.59% from its previous closing of Rs. 778.85 on the BSE.
The scrip opened at Rs. 797.95 and has touched a high and low of Rs. 800.55 and Rs. 785.45 respectively. So far 3289 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 838.45 on 15-Jul-2024 and a 52 week low of Rs. 430.00 on 18-Jul-2023.
Last one week high and low of the scrip stood at Rs. 838.45 and Rs. 715.00 respectively. The current market cap of the company is Rs. 17654.31 crore.
The promoters holding in the company stood at 49.17%, while Institutions and Non-Institutions held 34.79% and 16.05% respectively.
Zensar Technologies has acquired BridgeView Life Sciences LLC. The US?based leader in information technology and operations provides a comprehensive range of advisory, transformation, and managed services exclusively for life sciences customers endeavoring to launch products or new indications, assess and optimize their operations, or engage in merger or acquisition transactions. This strategic move strengthens Zensar's Healthcare and Life Sciences (HLS) vertical and expands its pharma commercial and product launch expertise.
The acquisition positions Zensar to offer a more comprehensive suite of solutions to pharmaceutical, biotechnology, and medical device companies. BridgeView's ‘Preferred Services Partner’ and ‘Services Partner’ status with Veeva Systems' Commercial Cloud and Development Cloud, respectively, solidify Zensar's position as a trusted technology partner. Additionally, BridgeView's partnerships with Reltio, Datavant, Snowflake, Salesforce, and IQVIA bolster its capabilities. The acquisition positions Zensar as a pivotal force in driving innovation and facilitating the digital transformation of life sciences companies, effectively addressing the industry's key challenges.
Zensar Technologies, formerly known as ICIL was acquired by the RPG group in 1989. It is a globally focused software and services company spread across eighteen countries across the world.
